| Literature DB >> 23437352 |
Jin-Kang Zhang1, Liu Yang, Guo-Lin Meng, Zhi Yuan, Jing Fan, Dan Li, Jian-Zong Chen, Tian-Yao Shi, Hui-Min Hu, Bo-Yuan Wei, Zhuo-Jing Luo, Jian Liu.
Abstract
Oxidative stress is a pivotal pathogenic factor for <span class="Disease">bone loss in <span class="Species">mouse model. Salidroside, a phenylpropanoid glycoside extracted from Rhodiola rosea L, exhibits potent antioxidative effects. In the present study, we used an in vitro oxidative stress model induced by hydrogen peroxide (H(2)O(2)) in MC3T3-E1 cells and a murine ovariectomized (OVX) osteoporosis model to investigate the protective effects of salidroside on bone loss and the related mechanisms. We demonstrated that salidroside caused a significant (P<0.05) elevation of cell survival, alkaline phosphatase (ALP) staining and activity, calcium deposition, and the transcriptional expression of Alp, Col1a1 and Osteocalcin (Ocn) in the presence of H(2)O(2). Moreover, salidroside decreased the production of intracellular reactive oxygen species (ROS), and osteoclast differentiation inducing factors such as receptor activator of nuclear factor-kB ligand (RANKL) and IL-6 induced by H(2)O(2). In vivo studies further demonstrated that salidroside supplementation for 3 months caused a decrease in malondialdehyde (MDA) and an increase in reduced glutathione (GSH) concentration in blood of ovariectomized mouse (P<0.05), it also improved trabecular bone microarchitecture and bone mineral density in the fourth lumbar vertebra and distal femur. Our study indicated that the protection provided by salidroside in alleviating bone loss was mediated, at least in part, via inhibition of the release of bone-resorbing mediators and oxidative damage to bone-forming cells, suggesting that salidroside can be used as an effective remedy in the treatment or prevention of osteoporosis.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23437352 PMCID: PMC3577746 DOI: 10.1371/journal.pone.0057251
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Chemical structure of salidroside.
Real-time PCR primers for amplification of specific MC3T3-E1 mRNA.
| Gene | Forward (5′–3′) | Reverse (5′–3′) |
|
| aacccagacacaagcattcc | ccagcaagaagaagcctttg |
|
| gcatggccaagaagacatcc | cctcgggtttccacgtctc |
|
| ctgacaaagccttcatgtccaa | gcgccggagtctgttcacta |
| β-actin | ctggcaccacaccttctaca | ggtacgaccagaggcataca |
Figure 2Protective effect of salidroside on H2O2 induced cytotoxicity in MC3T3-E1 cells.
A: Concentration- and time-dependent effects of H2O2 on cell viability. B: Cells were incubated in different concentrations of salidroside alone. C: Cells were pretreated with salidroside for 24 h before treatment with 0.3 mM H2O2 for 24 h. NAC was used as positive control. The control value for cell viability was 0.431±0.05 OD. ## P<0.01 versus untreated control cells; *P<0.05 and **P<0.01 compared with the group treated with H2O2 alone.
Figure 3Protective effect of salidroside on H2O2 induced osteoblast dysfunction.
After differentiation induction of 6 or 14 days, MC3T3-E1 cells were pretreated with salidroside for 24 h before treatment with 0.3 mM H2O2 for 24 h. NAC was used as positive control. A: Effect of salidroside on the ALP staining of MC3T3-E1 cells in the presence of H2O2. <$>\raster(70%)="rg1"<$> the control group; <$>\raster(70%)="rg2"<$> H2O2; <$>\raster(70%)="rg3"<$> H2O2+ salidroside (0.1µM); <$>\raster(70%)="rg4"<$> H2O2+ salidroside (1µM); <$>\raster(70%)="rg5"<$> H2O2+ salidroside (10µM); <$>\raster(70%)="rg6"<$> H2O2+NAC(1 mM). B: Effect of salidroside on the ALP activity of MC3T3-E1 cells in the presence of H2O2. The control value for ALP activity was 0.682 ± 0.021 unit /µg protein. C: Effect of salidroside on the mineralization of MC3T3-E1 cells in the presence of H2O2. The control value for mineralization was 1.392±0.31 OD. D: Effect of salidroside on the mRNA expression of Alp, Col-1 and Ocn in the presence of H2O2. # P<0.05 versus untreated control cells;*P<0.05 and **P<0.01 compared with the group treated with H2O2 alone.
Figure 4Inhibition of salidroside on RANKL and IL-6 production of MC3T3-E1 cells in the presence of H2O2.
After differentiation induction of 6 days, MC3T3-E1 cells were pretreated with salidroside for 24 h before treatment with 0.3 mM H2O2 for 24 h. NAC was used as positive control. A: The production of RANKL in the presence of salidroside and/or H2O2. The control value for RANKL was 3.792±0.271ng/mg. B: The production of IL-6 in the presence of salidroside and/or H2O2. The control value for IL-6 was 0.429±0.391 ng/mg. ## P<0.01 versus untreated control cells;*P<0.05 and **P<0.01 compared with the group treated with H2O2 alone.
Figure 5Inhibition of salidroside on reactive oxygen species generation induced by H2O2 in MC3T3-E1 cells.
After differentiation induction of 6 days, MC3T3-E1 cells were pretreated with salidroside for 24 h before treatment with 0.3 mM H2O2 for 24 h. NAC was used as positive control. The data shows changes in levels of ROS, which was measured by DCF fluorescence method. ## P<0.01 versus untreated control cells;*P<0.05 and **P<0.01 compared with the group treated with H2O2 alone.
Figure 6Inhibition of salidroside on oxidative status in serum of ovariectomized mice.
A: Serum MDA concentrations in ovariectomized mice supplemented with different concentration of salidroside. B: Serum GSH concentrations in ovariectomized mice supplemented with different concentration of salidroside. a: sham; b: OVX; c: OVX+salidroside (5 mg/kg); d: OVX+salidroside (20 mg/kg). The control value for MDA and GSH was 7.692±0.928 nM/mg and 13.24±1.391 nM/mg.## P<0.01 versus sham group;*P<0.05 compared with OVX group.
Effect of salidroside on bone microarchitecture indices in mice measured by Micro-CT.
| Indices | Sham | OVX | OVX+salidroside(5) | OVX+salidroside(20) |
|
| ||||
| BV/TV (%) | 0.107±0.029 | 0.031±0.004## | 0.041±0.002 | 0.073±0.011** |
| Tb.Th. (mm) | 0.032±0.003 | 0.021±0.002## | 0.025±0.002 | 0.028±0.004 |
| Tb.N. (1/mm) | 3.59±0.331 | 1.441±0.111## | 1.762±0.136 | 2.96±0.433** |
| Tb.Sp. (mm) | 0.250±0.024 | 0.676±0.053## | 0.579±0.048 | 0.317±0.047** |
| Conn.D (1/mm3) | 107.004±15.928 | 32.739±9.391## | 45.551±7.697 | 66.516±10.429** |
| SMI | 2.346±0.079 | 3.299±0.249## | 2.925±0.187** | 2.658±0.143** |
| BMD (mg/cm3) | 213.043±22.29 | 120.028±14.94## | 139.135±20.283 | 161.576±27.259** |
|
| ||||
| BV/TV (%) | 0.189±0.562 | 0.093±0.031## | 0.128±0.007** | 0.145±0.081** |
| Tb.Th. (mm) | 0.049±0.015 | 0.028±0.007## | 0.036±0.011 | 0.043±0.009 |
| Tb.N. (1/mm) | 4.753±1.427 | 2.897±0.678 | 3.745±1.087 | 4.054±0.873 |
| Tb.Sp. (mm) | 0.184±0.065 | 0.365±0.083## | 0.277±0.088 | 0.218±0.053 |
| Conn.D (1/mm3) | 154.732±17.973 | 68.537±12.338## | 85.447±13.46 | 119.781±15.749** |
| SMI | 1.649±0.183 | 2.524±0.12## | 2.171±0.21** | 1.867±0.159** |
| BMD (mg/cm3) | 183.984±20.14 | 92.661±15.592## | 121.059±26.827 | 143.759±22.349 |
Data were expressed as means ± S.D., n = 8 in each group.
P<0.05 and ## P<0.01vs. the sham group.
P<0.05 and ** P<0.01vs. the OVX group.
Figure 7Analysis of micro-computed tomography within the distal metaphyseal femur region.
A: sham, B: OVX, C: OVX+salidroside(5 mg/kg), D: OVX+salidroside(20 mg/kg).
Figure 8Van Gieson (VG) and Von Kossa (Silver nitrate) staining of the distal femur.
The figure was 40× of the original section.